Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Octreotide (Sandostatin) vs Pegvisomant (Somavert)
An educational, source-based comparison of Octreotide (Sandostatin) and Pegvisomant (Somavert) — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic somatostatin analog for acromegaly and neuroendocrine tumors.
An 8-amino-acid synthetic analog of somatostatin that binds somatostatin receptors (primarily SSTR2 and SSTR5), suppressing growth hormone, glucagon, insulin, and several gastrointestinal hormones. Longer half-life than native somatostatin enables therapeutic use.
- Acromegaly
- Carcinoid syndrome
- VIPomas
- Variceal bleeding
- Neuroendocrine tumors
- • FDA-approved.
- • Gallstones, hyperglycemia, GI upset are common adverse effects.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Octreotide (Sandostatin) | Octreotide LAR in acromegaly | NEJM | 2000 | Pivotal trial demonstrating normalization of GH and IGF-1 with monthly depot dosing. |
| Pegvisomant (Somavert) | Pegvisomant long-term acromegaly control | Lancet | 2001 | IGF-1 normalization in >90% on adequate doses. |
Side-effect & safety grid
- FDA-approved.
- Gallstones, hyperglycemia, GI upset are common adverse effects.
- FDA-approved.
- Monitor LFTs; tumor monitoring via MRI required.
- Lipohypertrophy at injection sites.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Octreotide (Sandostatin) vs Pegvisomant (Somavert) — Key differences
- Class: Octreotide (Sandostatin) is classified as Somatostatin Analog · Oncology, while Pegvisomant (Somavert) is GH Receptor Antagonist · Endocrine.
- Primary research focus: Octreotide (Sandostatin) — acromegaly; Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.
Octreotide (Sandostatin) — Frequently Asked Questions
Lanreotide versus octreotide — which has better outcomes?+
Randomized and observational studies in acromegaly and neuroendocrine tumors show broadly equivalent efficacy for lanreotide autogel and octreotide LAR at approved dose ranges — comparable biochemical response, tumor stabilization, and symptom control. Selection is typically driven by injection route (deep SC vs IM), self- or partner-administration preference, and tolerability, not raw efficacy.
Octreotide and lanreotide — are they interchangeable?+
They are the same drug class (somatostatin analogues, SSAs) but not identical drugs. Both bind somatostatin receptors (mainly SSTR2 and SSTR5) with comparable affinity profiles. Published switch protocols exist in both directions, but interchange is a clinical decision — not a like-for-like substitution.
What is the difference between octreotide and lanreotide administration?+
Octreotide LAR is a 6–8 mL intramuscular gluteal injection reconstituted from powder, administered by a healthcare professional. Lanreotide autogel is a pre-filled 0.5 mL deep-subcutaneous injection into the upper outer buttock and can be administered by a trained partner or, in some regions, by the patient.